About > Management Team
  • Li Chen, PhD

    Co-founder and CEO

    Dr. Li Chen, Co-founder and Board Director of Hua Medicine, leads Hua Medicine a clinical stage biotech company whose mission is to bring personalized diabetes medicines to patients in China and worldwide. He is a pioneer in collaborative innovation in China and advanced Hua Medicine with an operation principle of high standards, high quality and create high value. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Under his leadership, Hua Medicine completed successfully a POC study and initiated China NDA enabling process. During this period, Hua Medicine raised 100M USD and established the leading position of Hua Medicine in China biotech industry.

    Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 35 granted patents and an author with over 60 publications.

  • George Lin, J.D.

    EVP & Chief Financial Officer

    Mr. George Lin, J.D., a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally.  Prior to joining Hua Medicine, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and Head of Hong Kong and Taiwan Investment Banking for Bank of America Merrill Lynch based in Hong Kong.  As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was previously based in Los Angeles and San Francisco before moving to Hong Kong in 2007.  His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe.  In the last 10 years alone, Mr. Lin has led M&A transactions valued (in aggregate) in excess of US$20 billion and raised financings valued (in aggregate) at over US$40 billion.

    Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.

    As Hua's EVP and CFO, Mr. Lin's responsibilities will include corporate finance, business development and licensing / partnering efforts.

  • Daniel Du, PhD, M.D.

    SVP, Regulatory, Medical Safety and Manufacture

    Dr. Daniel Du has worked in pharmaceutical industry for more than 20 years with broad experience in drug discovery, clinical development and regulatory submission. He was instrumental in discovery of multiple clinical candidates and played significant roles in multiple IND and NDA submissions when he was working in two of the fortune 500 pharmaceutical companies. He is also a skilled clinician and medical monitor for clinical studies, experienced in safety management, and authored the clinical sections for multiple NDA filings. He is the inventor of over 15 patents and authored over 20 manuscripts. Dr. Daniel Du received Medical degree from Beijing Medical University and PhD of Pharmacology and Toxicology from Albany Medical College, NY. He received US Education Certificates for Foreign Medical Graduates (ECFMG).

  • Yi Zhang, PhD, M.D.

    VP, Clinical R&D

    Dr. Yi Zhang heads the clinical research & development team at Hua Medicine. Prior to joining Hua, Dr. Zhang was the Associate Medical Director of Clinical Science at Roche Product Development group, Asia Pacific region. She served as a clinical scientist for innovative drug development in the areas of cardiovascular, metabolic and renal diseases. Prior to Roche, Dr. Zhang was a Physician and an Associate Professor at Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine with more than 10 years' clinical experience. Dr. Zhang was also a team leader of the molecular genetics research group at the Shanghai Institute of Hypertension and a principle investigator for several projects supported by the National Natural Science Foundation of China and the Shanghai Municipal Natural Science Foundation. Dr. Zhang obtained her MD and PhD from Shanghai Jiaotong University School of Medicine, specialized in cardiology. She received training in molecular genetics, bioinformatics and epidemiology at the Chinese National Human Genome Center and at the Framingham Heart Study as a NIH/NHLBI visiting researcher. Dr. Zhang has received Shanghai Subject Chief Scientist and 60 publications in journals such as Nat Genet, Circ Cardiovasc Genet, Hum Mol Genet, 4 book chapters, and has 3 China patents.

  • Fred Li, PhD

    VP, CMC

    Dr. Yong-Guo Li (Fred) serves as VP Pharmaceutical R&D at Hua Medicine (Shanghai) Limited, an innovative biotech company focused on developing novel therapeutics. His major responsibilities include overseeing Chemistry, Manufacture & Control (CMC) and Drug Supply, GxP compliance, and supervising Corporate Project Management. Prior to joining Hua Medicine, Dr. Li worked at Roche’s R&D Center (China) for nearly 8 years as Head of Analytics and Deputy Head of the CMC Department. He also served as a member of the Senior Management Team, Research Project Management Team, Metabolic Project Leadership Team, and was an acting Officer of Environmental Safety and Health (EHS). Before Roche, Dr. Li worked at the global healthcare company Pharmanex as the Head of Analytics and Quality Assurance for 8 years. He was also a faculty member of China Pharmaceutical University for 5 years. He has published over 20 scientific articles in peer-reviewed journals and is an author of 4 book chapters. Fred is currently an Adjunct Professor at Shanghai University of Chinese Medicine.

  • Jin She, PhD

    VP, Chemistry

    Dr. Jin She is responsible for API manufacturing, Process Chemistry Research & Development, and Discovery Chemistry at Hua. Dr. She has over 11 years’ experience in the biotechnology and pharmaceutical industry. Prior to joining Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research &Synthesis. Before returning back to China from the US, he worked at Inspire Pharmaceuticals Inc. as Sr. Research Scientist and team leader of Process Research. Dr. She has also been an Industrial Advisor for Engineering Master Program at East China Science & Technology University for the last 5 years.He has 8 publications in peer-reviewed journals and 6 patents. Dr. She Received his PhD in organic chemistry from the University of North Carolina at Chapel Hill. He obtained his BS and MS degrees in chemistry from Beijing University.
  • Fu Yilei, MBA

    VP, Quality Assurance

    A seasoned leader in quality control and assurance with over 20 years experiences in the Pharma industry across sites and countries at AstraZeneca, Xian Janssen and Boehringer-Ingelheim (Germany & China). In his extensive knowledge and experience with proven track records for hosting various regulatory GMP, GSP inspection successfully include EU, TGA and CFDA authorities. Also Mr. Fu have rich hands-on experience for leading company Quality Culture change, continuous improvement of quality management systems and building high performing quality team. He is taking overall quality management responsibilities for Hua’s QMS systems and as executive co-chairman for Quality & Safety committee. Mr.  Fu is licensed pharmacist and owns master degree of business administration from Shanghai Jiaotong University.

  • Paul Kong

    VP, Clinical Operation

    Paul Kong, leads Clinical Operation Department within Hua Medicine. His main responsibility includes the development of strategies and plans for Clinical Operation that supporting the company’s goals, proactive implementation of operation plan to ensure the effective delivery of clinical study results. Prior to joining Hua Medicine, he served as Head of Clinical Operation of FibroGen China since Nov 2013, where he completed a multiple pivotal Ph III trials for HIF-PHI in China, which is going to be the first time that the world first class drug completed NDA enabling clinical study in China before anywhere else in the world. From 2012 to 2013, he was Global Study Manager in Roche China, where he managed a global phase III trial which involved 50 countries. Before Roche, he held the position of Head of Clinical Operation in Fountain Medical Development since 2008, where he set up the operation team as well as the operation system to oversight the team/study not only in mainland China, but also Hong Kong, Korea and Taiwan. He started his clinical research career from Parexel. Paul Kong received a Master in Pharmacy from China Pharmaceutical University.

  • Haoliang Song, PhD

    Senior Director, Preclinical Drug Safety

    Dr. Haoliang Song is Director, Drug Safety Assessment at Hua Medicine. Now he is managing all the drug safety-related studies, cooperating with the partners from US, China and other countries. As a member of Hua Medicine QQLT, Dr. Song also attends the Quality control strategic development of Hua Medicine projects. Dr. Song has more than 16 years experience in hospital and biotechnology company. Before joining the company, Dr. Song worked at Medicilon as Director of Operations and Study Director to lead teams in the development of GLP and non-GLP preclinical studies. He received USFDA GLP regulation and study trainings including study design and study operations & management at US MPI RESEARCH. Prior to that, Dr. Song spent several years at Hong Kong Polytechnic University as Research associate and its institute of Modern Chinese Medicine as Head of Pharmacology department, leading teams in the development of pharmacology and toxicology techniques platform, where he completed the studies for the doctoral thesis. Dr. Song also had five years working experience in hospital, where he had more close attention on how to meet the patients’ needs. Dr. Song is the author of more than 10 publications and one of the inventors of 4 patents.

  • Michelle Zhu

    Senior Director, Industrial Policy & Regulation

    Michelle is a seasoned leader in China pharmaceutical policy and regulation over 20 years in China with rich experience in market access and government policies. Prior to joining Hua Medicine, she has worked with Boehringer-Ingelheim, Abbott and J&J China operation and established her leadership in the drug price negotiation, market entry and establishment of joined ventures. She was in charge of market access affairs and responsible for developing government affairs strategies to achieve company’s business goal. Michelle has also managed government relation operation, which focused on reimbursement and pricing. She cooperated with government agencies/organizations and Industry Associations for monitoring central and provincial government policy changes.


  • Gary Yu

    Senior Director, Regulatory Affairs

    Gary Yu,Master of pharmaceutics, senior engineer. Now he serves as Director of Regulatory Affairs in Division of Clinical Research and Development. Prior to join Hua, Gary was in charge of two developing projects of innovative T2DM drug candidates and managed a series of tasks that preclinical evaluation, clinical development and regulatory affairs are included. One of these projects was supported by National Key Technologies R&D Program and has been accomplished in 2013. Gary has more than 10 years’ experience of Medical R&D project management and Pharmaceutical license progress. Gary has also participated as inventor in writing and registration of several domestic and PCT patents.

  • Xiaowei Jin, PhD

    Director, Biology

    Dr. Jin has over 16 years of experience in the biopharmaceutical industry. She was formerly Vice President of Discovery Biology at Medicilon, responsible for building and managing its Discovery Biology infrastructure. She has extensive experience in the areas of CNS disorders, inflammation, oncology, metabolic and cardiovascular diseases. Before returning to China, she was Team Leader for the Neurodegenerative Disease Focus Area at CombinatoRx, leading several programs in the CNS area, including Spinal Muscular Atrophy and Huntington Disease. Prior to that, she was a research scientist in the Pharmacology Department at Biogen, in charge of the molecular pharmacology function to support multiple programs in the CNS and cardiovascular disease areas including congestive heart failure and Parkinson Disease. 
    Dr. Jin received her PhD in Biochemistry and Pharmacology from the University of Virginia and completed her postdoctoral training at Harvard Medical School. She received her BS from the University of Science & Technology of China with highest honors. Dr. Jin has published more than 20 research papers and review articles in international journals such as Cell, Neuron, Nature Biotech., JCI, Molecular Pharmacology and MCB, and has served as invited speaker in many national and international conferences. She is also an inventor on several US national and world-wide international patents.

  • Shuang Ren, PhD

    Director, Clinical Pharmacology

    Dr. Shuang Ren is responsible for Bioanalytical, Preclinical Pharmacology, and Clinical Pharmacology at Hua Medicine. Dr. Ren has over 11 years’ experience in drug research and development at various top 10 international pharmaceutical companies as clinical pharmacologist and DMPK project leader in different disease areas (metabolic diseases, respiratory disease, oncology, CNS and infectious disease). Prior to Hua Medicine, she worked at the Novartis Institutes for Biomedical Research (NIBR) Shanghai Center as Investigator in Clinical Pharmacology, and Roche R&D Center (China) as Senior Scientist in DMPK. Dr. Ren received her PhD in molecular biology and biochemistry from Tong Ji University. 

  • Howard Hou, MD

    Medical Director

    Dr. Hou serves as Medical Director at Hua Medicine responsible for medical sciences and monitoring of clinical studies.  Dr. Hou is an experienced medical professional who worked at Merck, Pfizer and AstraZeneca in the areas of medical monitoring and as medical liaison in the last 10 years in diabetes and cardiovascular disease, where he received many awards for his contribution to advance drug development. Dr. Hou received his medical degree from China Medical University and worked as a physician in cardiology at The 1st Hospital of China Medical University for several years.  Dr. Hou went on for further training and received his MD from Institute for Molecular and Cellular Regulation in Japan, and continued his post-doctoral research in USA. Dr. Hou completed his post-doc research with honor at Albert Einstein and is an author of 10 publications.  


  • Copyright © 2018 Hua Medicine, All Rights Reserved